- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Comprehensive Molecular Testing in Patients With Ovarian Cancer
A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a timely manner for patients with ovarian cancer, emphasizing the need for better education of health care providers and more affordable, widely available testing options.
EP: 1.The Role of Guidelines on Molecular Testing in Ovarian Cancer
EP: 2.FRα Biomarker Testing in Patients With Ovarian Cancer
EP: 3.Emerging Molecular Biomarkers in Ovarian Cancer
EP: 4.Comprehensive Molecular Testing in Patients With Ovarian Cancer
EP: 5.The Impact of Tumor Heterogeneity in Ovarian Cancer
EP: 6.Improving Clinician Awareness and Adoption of Molecular Testing
EP: 7.Antibody-Drug Conjugates for Platinum-Resistant Ovarian Cancer
EP: 8.The Role of Novel Targeted Therapies
EP: 9.The Use of PARP Inhibitors in Ovarian Cancer
EP: 10.Earlier Introduction of Antibody-Drug Conjugates
EP: 11.Approaching Treatment Sequencing In Heavily Pretreated Patients
EP: 12.Single-Agent Vs Combination Regimens
EP: 13.The Potential Impact of Investigational Therapies
EP: 14.Learnings From Key Clinical Trials in Ovarian Cancer
Video content above is prompted by the following:
Challenges in Comprehensive Molecular Testing
Two primary barriers impact comprehensive molecular testing implementation:
Education:
- Physicians need better awareness about which tests to order, when to order them, and how to interpret results.
- All patients with advanced or recurrent disease should receive comprehensive testing (DNA, RNA, and protein analysis).
- Education must extend to health care providers, patients, and the broader community.
Cost and reimbursement:
- Medicare covers several biomarker tests with little to no patient cost.
- Reimbursement varies by insurance type, with inconsistencies in federal and state funding.
- Improving value requires both better education and more affordable testing options.
Addressing these barriers would support wider adoption of comprehensive molecular testing in ovarian cancer.
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis
June 19th 2025Telitacicept is a dual-targeting agent that attaches to and blocks the effects of 2 key signaling proteins, B-lymphocyte stimulator and a proliferation-inducing ligand, to treat the B-cell–mediated autoimmune disease, generalized myasthenia gravis.
Read More
